Modulation of Bile Acid Metabolism to Improve Plasma Lipid and Lipoprotein Profiles
Open Access
- 21 December 2021
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (1) , 4
Abstract
New drugs targeting bile acid metabolism are currently being evaluated in clinical studies for their potential to treat cholestatic liver diseases, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Changes in bile acid metabolism, however, translate into an alteration of plasma cholesterol and triglyceride concentrations, which may also affect cardiovascular outcomes in such patients. This review attempts to gain insight into this matter and improve our understanding of the interactions between bile acid and lipid metabolism. Bile acid sequestrants (BAS), which bind bile acids in the intestine and promote their faecal excretion, have long been used in the clinic to reduce LDL cholesterol and, thereby, atherosclerotic cardiovascular disease (ASCVD) risk. However, BAS modestly but consistently increase plasma triglycerides, which is considered a causal risk factor for ASCVD. Like BAS, inhibitors of the apical sodium-dependent bile acid transporter (ASBTi’s) reduce intestinal bile acid absorption. ASBTi’s show effects that are quite similar to those obtained with BAS, which is anticipated when considering that accelerated faecal loss of bile acids is compensated by an increased hepatic synthesis of bile acids from cholesterol. Oppositely, treatment with farnesoid X receptor agonists, resulting in inhibition of bile acid synthesis, appears to be associated with increased LDL cholesterol. In conclusion, the increasing efforts to employ drugs that intervene in bile acid metabolism and signalling pathways for the treatment of metabolic diseases such as NAFLD warrants reinforcing interactions between the bile acid and lipid and lipoprotein research fields. This review may be considered as the first step in this process.Keywords
Funding Information
- China Scholarship Council (CSC202006170047)
- Netherlands Heart Foundation (IN CONTROL, CVON2018-27)
This publication has 159 references indexed in Scilit:
- Initial combination therapy with metformin plus colesevelam improves lipoprotein particles in patients with early type 2 diabetes mellitusJournal of Clinical Lipidology, 2012
- TGR5 Activation Inhibits Atherosclerosis by Reducing Macrophage Inflammation and Lipid LoadingCell Metabolism, 2011
- Hepatic Overexpression of Abcb11 Promotes Hypercholesterolemia and Obesity in MiceGastroenterology, 2011
- Constipation and Risk of Cardiovascular Disease among Postmenopausal WomenThe American Journal of Medicine, 2011
- The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?Journal of Lipid Research, 2010
- Identification of Novel Pathways That Control Farnesoid X Receptor-mediated HypocholesterolemiaJournal of Biological Chemistry, 2010
- Bile acid transportersJournal of Lipid Research, 2009
- TGR5-Mediated Bile Acid Sensing Controls Glucose HomeostasisCell Metabolism, 2009
- Targeted deletion of Gpbar1 protects mice from cholesterol gallstone formationBiochemical Journal, 2006
- Protein Sensors for Membrane SterolsCell, 2006